Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

New Standards of Care for Advanced Prostate CancerПодробнее

Dr. Oh on the Management of Hormone-Sensitive Prostate CancerПодробнее

William K. Oh, MD, on the real-world analysis of abiraterone & docetaxel in mHSPCПодробнее

2022 ASCO Genitourinary Cancers Symposium Research Updates Webinar with Dr. Alexandra SokolovaПодробнее

Dr. Oh Discusses the Use of Abiraterone and Docetaxel in Prostate CancerПодробнее

Management of Advanced Hormone-sensitive and Castration-resistant Prostate CancerПодробнее

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic reviewПодробнее

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer TreatmentПодробнее

Dr. Oh Discusses the Role of Chemotherapy in Prostate CancerПодробнее